Page 23 - Read Online

Bhasin et al. J Transl Genet Genom 2024;8:55-76 https://dx.doi.org/10.20517/jtgg.2023.46 Page 71

6. Thomas DA, Massagué J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer
Cell 2005;8:369-80. DOI PubMed
7. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med
2010;363:711-23. DOI
8. Motzer RJ, Escudier B, McDermott DF, et al; CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell
carcinoma. N Engl J Med 2015;373:1803-13. DOI
9. Schmid P, Adams S, Rugo HS, et al; IMpassion130 Trial Investigators. Atezolizumab and nab-paclitaxel in advanced triple-negative
breast cancer. N Engl J Med 2018;379:2108-21. DOI
10. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-
small-cell lung cancer. N Engl J Med 2018;378:2078-92. DOI
11. Kantoff PW, Higano CS, Shore ND, et al; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate
cancer. N Engl J Med 2010;363:411-22. DOI
12. Tucker MD, Zhu J, Marin D, et al. Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer. Cancer
Med 2019;8:4644-55. DOI PubMed PMC
13. Subudhi SK, Siddiqui BA, Aparicio AM, et al. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve
metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone
microenvironment. J Immunother Cancer 2021;9:e002919. DOI PubMed PMC
14. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med
2012;366:2443-54. DOI PubMed PMC
15. Petrylak DP, Loriot Y, Shaffer DR, et al. Safety and clinical activity of atezolizumab in patients with metastatic castration-resistant
prostate cancer: a phase I study. Clin Cancer Res 2021;27:3360-9. DOI
16. Powles T, Yuen KC, Gillessen S, et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant
prostate cancer: a randomized phase 3 trial. Nat Med 2022;28:144-53. DOI PubMed PMC
17. Agarwal N, McGregor B, Maughan BL, et al. Cabozantinib in combination with atezolizumab in patients with metastatic castration-
resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncol
2022;23:899-909. DOI
18. Karzai F, VanderWeele D, Madan RA, et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in
men with and without DNA damage repair mutations. J Immunother Cancer 2018;6:141. DOI PubMed PMC
19. Hotte S, Winquist E, Chi K, et al. CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with
metastatic castration resistant prostate cancer (mCRPC). Ann Oncol 2019;30:v885. DOI
20. Antonarakis ES, Piulats JM, Gross-Goupil M, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate
cancer: multicohort, open-label phase II keynote-199 study. J Clin Oncol 2020;38:395-405. DOI
21. Graff JN, Tagawa ST, Hoimes CJ, et al. Pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration- resistant
prostate cancer (mCRPC): updated analyses after one additional year of follow-up from cohorts 4 and 5 of the keynote-199 study.
2021;39:5042. DOI
22. Yu EY, Piulats JM, Gravis G, et al. Pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer: long-
term results from the phase 1b/2 keynote-365 cohort a study. Eur Urol 2023;83:15-26. DOI
23. Beer TM, Kwon ED, Drake CG, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or
minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol 2017;35:40-7.
DOI PubMed
24. Kwon ED, Drake CG, Scher HI, et al; CA184-043 Investigators. Ipilimumab versus placebo after radiotherapy in patients with
metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre,
randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15:700-12. DOI
25. Shenderov E, Boudadi K, Fu W, et al. Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic
castration-resistant prostate cancer: a phase-2 nonrandomized clinical trial. Prostate 2021;81:326-38. DOI PubMed PMC
26. Goebeler ME, Bargou RC. T cell-engaging therapies - BiTEs and beyond. Nat Rev Clin Oncol 2020;17:418-34. DOI PubMed
27. Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol 2015;93:290-6. DOI
PubMed PMC
28. Simão DC, Zarrabi KK, Mendes JL, et al. Bispecific t-cell engagers therapies in solid tumors: focusing on prostate cancer. Cancers
2023;15:1412. DOI PubMed PMC
29. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol 2009;27:591-619. DOI PubMed PMC
30. Einsele H, Borghaei H, Orlowski RZ, et al. The BiTE (bispecific T-cell engager) platform: development and future potential of a
targeted immuno-oncology therapy across tumor types. Cancer 2020;126:3192-201. DOI
31. Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs 2017;9:182-212. DOI PubMed PMC
32. Vinay DS, Ryan EP, Pawelec G, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol
2015;35 Suppl:S185-98. DOI PubMed
33. Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. Induction of regular cytolytic T cell synapses by bispecific single-chain
antibody constructs on MHC class I-negative tumor cells. Mol Immunol 2006;43:763-71. DOI PubMed
34. Ross SL, Sherman M, McElroy PL, et al. Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell